Gastric cancer, surgical resection, HER-2 positive, chemotherapy, adenocarcinoma
Gastroenterology | Medicine and Health Sciences | Oncology | Surgery
Background. Gastric cancer has a low overall survival rate worldwide, and surgery still remains the intent to cure option on early stages of disease. HER-2 positive cancers may have a survival advantage. We present a patient with stage IV gastric cancer HER-2 positive responsive to Herceptin, free of detectable disease two years after surgery.
Patient Presentation. 70 years old Caucasian male complained of left-sided chest pain. Upon evaluation, he was diagnosed with HER-2 positive adenocarcinoma of the stomach at the pylorus with two liver metastases. Near complete response was observed with Herceptin and Cis-platinum based chemotherapy followed by 80% distal gastrectomy and liver resection with uneventful recovery. Two years follow up reported a patient living normal life with undetectable disease.
Conclusion. Multimodality targeted therapy may accomplish 24months cure of advanced malignant gastric disease.
Mohammed, Ibrahim; Nagisetty, Cherishma; Iqbal, Arslan; Abdelmasseh, Michael; Griswold, Doreen; Jamil, Muhammad Omer; and Sanabria, Juan R.
"Eradication of Stage IV Gastric Cancer: Case Report,"
Marshall Journal of Medicine:
3, Article 5.
Available at: https://mds.marshall.edu/mjm/vol6/iss3/5